Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs ONC 201 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 19 Mar 2018 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.
- 28 Mar 2017 Status changed from active, no longer recruiting to recruiting.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.